Darzalex sales exceed expectations in second quarter

Sales of Johnson & Johnson's drug Darzalex totaled USD 1.43bn in Q2, far surpassing analysts' expectations for the drug, which was originally developed by Genmab.

Photo: Tuala Hjarnø / Genmab / PR

At the half-way point of 2021, Genmab-developed drug Darzalex is close to achieving triple-blockbuster status, after a significant growth in sales compared to last year.

Johnson & Johnson report that sales of Darzalex in Q2 alone totaled USD 1.43bn, up from USD 901m for the same period last year. This brings the total sales for the first half of 2021 up to USD 2.8bn.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs